Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy

키워드

참고문헌 (37)

1. Coiffier B., "Diffuse large cell lymphoma", Curr Opin Oncol, 13, pp.325~334 (2001)
2. Rossi D, "Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis", Hematology, 7, pp.239~252 (2002)
3. Lenz G, "Stromal gene signatures in large-B-cell lymphomas", N Engl J Med, 359, pp.2313~2323 (2008)
4. Akay OM, "BCL2, BCL6, IGH, TP53, and MYC protein expression and gene rearrangements as prognostic markers in diffuse large B-cell lymphoma: a study of 44 Turkish patients", Cancer Genet, 207, pp.87~93 (2014)
5. Liotta LA, "The microenvironment of the tumour-host interface", Nature, 411, pp.375~379 (2001)
6. Schreiber RD, "Cancer immunoediting:integrating immunity’s roles in cancer suppression and promotion", Science, 331, pp.1565~1570 (2011)
7. Fontenot JD, "A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3", Nat Immunol, 6, pp.331~337 (2005)
8. Tzankov A, "Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma", Haematologica, 93, pp.193~200 (2008)
9. Beyer M, "Regulatory T cells in cancer", Blood, 108, pp.804~811 (2006)
10. Banchereau J, "Dendritic cells and the control of immunity", Nature, 392, pp.245~252 (1998)
11. Banchereau J, "Immunobiology of dendritic cells", Annu Rev Immunol, 18, pp.767~811 (2000)
12. Lanzavecchia A, "The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics", Curr Opin Immunol, 13, pp.291~298 (2001)
13. Gabrilovich D., "Mechanisms and functional significance of tumour-induced dendritic-cell defects", Nat Rev Immunol, 4, pp.941~952 (2004)
14. Dubsky P, "Human dendritic cell subsets for vaccination", J Clin Immunol, 25, pp.551~572 (2005)
15. Steinman RM, "Taking dendritic cells into medicine", Nature, 449, pp.419~426 (2007)
16. Palucka K, "Designing vaccines based on biology of human dendritic cell subsets", Immunity, 33, pp.464~478 (2010)
17. Shortman K, "Mouse and human dendritic cell subtypes", Nat Rev Immunol, 2, pp.151~161 (2002)
18. Spits H, "Natural killer or dendritic: what’s in a name?", Immunity, 26, pp.11~16 (2007)
19. Campo E, "The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications", Blood, 117, pp.5019~5032 (2011)
20. Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
21. Sweetenham JW., "Diffuse large B-cell lymphoma : risk stratification and management of relapsed disease", Hematology Am Soc Hematol Educ Program, pp.252~259 (2005)
22. Alizadeh AA, "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403, pp.503~511 (2000)
23. Shiozawa E, "The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries", Leuk Res, 31, pp.1579~1583 (2007)
24. 황희상, "Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma", Blood Research, 48(4), pp.266~273 (2013), 대한혈액학회
25. Lopez-Guillermo A, "Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin", J Clin Oncol, 23, pp.2797~2804 (2005)
26. Abramson JS, "Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach", Blood, 106, pp.1164~1174 (2005)
27. Moller MB, "Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation: a population-based study of 1575cases", Br J Haematol, 124, pp.151~159 (2004)
28. d’Amore F, "Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group", Eur J Cancer, 27, pp.1201~1208 (1991)
29. Houldsworth J, "REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma", Blood, 87, pp.25~29 (1996)
30. Gronbaek K, "Somatic Fas mutations in non-Hodgkin’s lymphoma: association with extranodal disease and autoimmunity", Blood, 92, pp.3018~3024 (1998)
31. Sakaguchi S, "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases", J Immunol, 155, pp.1151~1164 (1995)
32. Li B, "FOXP3 ensembles in T-cell regulation", Immunol Rev, 212, pp.99~113 (2006)
33. Coutinho R, "Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry:robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP", Haematologica, 100, pp.363~369 (2015)
34. Lee NR, "Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis", Leuk Lymphoma, 49, pp.247~256 (2008)
35. Shurin MR, "Intratumoral cytokines", chemokines, Cancer Metastasis Rev, pp.2006, 25[DOI]
36. Middle S, "Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins", Exp Hematol Oncol, 4, pp.10~ (2015)
37. Upadhyay R, "Lymphoma: immune evasion strategies", Cancers (Basel), 7, pp.736~762 (2015)

관련 논문AI추천